Chronic Exposure to Malaria Is Associated with Inhibitory and
                Activation Markers on Atypical Memory B Cells and Marginal
                Zone-Like B Cells by Ubillos, Itziar et al.
August 2017 | Volume 8 | Article 9661
Original research
published: 21 August 2017
doi: 10.3389/fimmu.2017.00966
Frontiers in Immunology | www.frontiersin.org
Edited by: 
Deborah K. Dunn-Walters, 
University of Surrey, 
United Kingdom
Reviewed by: 
Carl De Trez, 









This article was submitted 
to B Cell Biology, 






Ubillos I, Campo JJ, Requena P, 
Ome-Kaius M, Hanieh S, Rose H, 
Samol P, Barrios D, Jiménez A, 
Bardají A, Mueller I, Menéndez C, 
Rogerson S, Moncunill G and 
Dobaño C (2017) Chronic Exposure 
to Malaria Is Associated with 
Inhibitory and Activation Markers on 
Atypical Memory B Cells and 
Marginal Zone-Like B Cells. 
Front. Immunol. 8:966. 
doi: 10.3389/fimmu.2017.00966
chronic exposure to Malaria is 
associated with inhibitory and 
activation Markers on atypical 
Memory B cells and Marginal  
Zone-like B cells
Itziar Ubillos1, Joseph J. Campo1,2, Pilar Requena1,3, Maria Ome-Kaius4, Sarah Hanieh4, 
Honor Rose4, Paula Samol 4, Diana Barrios1, Alfons Jiménez1,5, Azucena Bardají 1,  
Ivo Mueller4,6, Clara Menéndez1, Stephen Rogerson7, Gemma Moncunill 1 and  
Carlota Dobaño1*
1 ISGlobal, Barcelona Ctr. Int. Health Res. (CRESIB), Hospital Clínic-Universitat de Barcelona, Barcelona, Spain,  
2 Antigen Discovery Inc., Irvine, CA, United States, 3 Facultad de Medicina, Universidad de Granada, Granada, Spain, 4 Papua 
New Guinea Institute of Medical Research, Madang, Papua New Guinea, 5 CIBER Epidemiology and Public Health 
(CIBERESP), Barcelona, Spain, 6 Walter and Eliza Hall Institute of Medical Research, Parkville, VIC, Australia, 7 University of 
Melbourne, Melbourne, VIC, Australia
In persistent infections that are accompanied by chronic immune activation, such as 
human immunodeficiency virus, hepatitis C virus, and malaria, there is an increased fre-
quency of a phenotypically distinct subset of memory B cells lacking the classic memory 
marker CD27 and showing a reduced capacity to produce antibodies. However, critical 
knowledge gaps remain on specific B cell changes and immune adaptation in chronic 
infections. We hypothesized that expansion of atypical memory B cells (aMBCs) and 
reduction of activated peripheral marginal zone (MZ)-like B cells in constantly exposed 
individuals might be accompanied by phenotypic changes that would confer a tolerogenic 
profile, helping to establish tolerance to infections. To better understand malaria-asso-
ciated phenotypic abnormalities on B cells, we analyzed peripheral blood mononuclear 
cells from 55 pregnant women living in a malaria-endemic area of Papua Nueva Guinea 
and 9 Spanish malaria-naïve individuals using four 11-color flow cytometry panels. We 
assessed the expression of markers of B cell specificity (IgG and IgM), activation (CD40, 
CD80, CD86, b220, TACI, and CD150), inhibition (PD1, CD95, and CD71), and migration 
(CCR3, CXCR3, and CD62l). We found higher frequencies of active and resting aMBC 
and marked reduction of MZ-like B  cells, although changes in absolute cell counts 
could not be assessed. Highly exposed women had higher PD1+-, CD95+-, CD40+-, 
CD71+-, and CD80+-activated aMBC frequencies than non-exposed subjects. Malaria 
exposure increased frequencies of b220 and proapoptotic markers PD1 and CD95, and 
decreased expression of the activation marker TACI on MZ-like B cells. The increased 
frequencies of inhibitory and apoptotic markers on activated aMBCs and MZ-like B cells 
in malaria-exposed adults suggest an immune-homeostatic mechanism for maintaining 
B  cell development and function while simultaneously downregulating hyperreactive 
B  cells. This mechanism would keep the B  cell activation threshold high enough to 
control infection but impaired enough to tolerate it, preventing systemic inflammation.
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inTrODUcTiOn
In persistent infections that are accompanied by chronic immune 
activation, such as human immunodeficiency virus (HIV), 
hepatitis C virus (HCV), and malaria, there is constant polyclonal 
proliferation of antigen-specific B  cells. In such cases, homeo-
static mechanisms to attenuate chronic antigenic stimulation 
are necessary to downregulate activation pathways and allow for 
host tolerance (1–3). The expression “tolerance to malaria infec-
tion,” in particular, has long been used to explain the fact that in 
endemic areas Plasmodium infection can occur without malaria 
disease (4).
It is accepted that in malaria and other chronic infections, 
sterilizing immunity rarely occurs (5, 6) and highly exposed 
individuals may be carriers of low-density asymptomatic infec-
tions (5, 7). In addition, there is increasing evidence that chronic 
Plasmodium parasitemia evades antibody-mediated immunity 
through dysregulation of CD4+ T  cell and B  cell function (5). 
Exposure-dependent tolerogenic antibody and cell-mediated 
responses likely avoid full clearance of parasitemia, a phenom-
enon known also as premunition (4, 7, 8).
In an effective adaptive immune response, activated B  cells 
undergo a process of class switching recombination, somatic 
hypermutation (SHM) and affinity selection within the germinal 
center (GC) to generate long-lived plasma cells (9), memory B cells 
(MBCs), and protective antibodies (10). The adaptive response to 
an infection is a tightly controlled process in which inhibitory and 
proapoptotic receptors such as Fas/CD95 and PD1 (programmed 
death 1) play an important role in regulating cell survival (11, 12). 
In chronic infections like HIV (13) and malaria (14), and also in 
autoimmune diseases like rheumatoid arthritis (15) and systemic 
lupus erythematosus (16), there is upregulation of inhibitory and 
proapoptotic receptors on B  cells coupled with increased fre-
quency of a phenotypically distinct MBC subset lacking the classic 
memory marker CD27 (2, 3, 17, 18) and usually accompanied 
by an increase of IgD−CD27+ classical MBC (19–21). Studies of 
HIV- and HCV-infected individuals suggested that this CD27− 
MBC subset may be prone to anergy and/or apoptosis, because 
they expressed PD1, FcRL4, FcRL5, and CD95 and had a reduced 
capacity to proliferate (17, 19, 22). This phenotype gave rise to 
the denomination of these cells as “exhausted.” A phenotypically 
similar subset called “atypical MBC” (aMBC) has been associated 
with malaria exposure (3, 18, 23–28). The role of the anergic and/
or exhausted aMBC in chronic infection is still unknown.
Chronic immune activation also affects circulating 
IgM+CD19+CD27+ MBC, which frequency is greatly reduced in 
HIV (22) and malaria (18, 26, 29). This B cell subset is similar 
to marginal zone (MZ)-like B cells, found mainly in secondary 
lymphoid organs (30) and to a lesser extent in peripheral blood. 
They link innate and later-occurring adaptive responses and 
are key to extracellular antigen responses (31). Recent studies 
highlight the importance of IgM-expressing B cells in generating 
T-independent rapid and avid response to an infection (32–34). 
However, their role in chronic infection is unclear.
A common limitation of past studies is the imprecise pheno-
typical classification of MBC subsets. We have shown that inclu-
sion of IgD in cytometry panels to distinguish between switched 
(IgD−) and unswitched (IgD+) B cells improved the specificity of 
MBC classification (18). Indeed, our previous work showed that a 
substantial frequency of CD27−CD21+, presumably naïve B cells, 
were actually switched MBC lacking CD27 (resting aMBC) and, 
conversely, that a substantial proportion of CD27−CD21−, pre-
sumably aMBC (aMBC) were actually IgD+ and may represent a 
phenotypically distinct population (18).
Here, we investigated the surface expression of multiple 
activation-, inhibition- and survival-associated B  cell markers 
in peripheral blood mononuclear cells (PBMCs) from malaria-
exposed and malaria-naïve donors to characterize cellular 
phenotypes. We hypothesized that expansion of aMBC with a 
tolerogenic-like phenotype and reduction of activated peripheral 
MZ-like B cells in constantly exposed individuals may be a com-
plementary mechanism to downregulate continuously activated 
B cells while simultaneously maintaining B cell functions, helping 
to establish tolerance to the infection (15, 17).
MaTerials anD MeThODs
study Participants
The study recruited 55 malaria-exposed pregnant women from 
the Madang Province in Papua New Guinea (PNG) at their first 
antenatal clinic visit between 2008 and 2010 (Table 1) and 9 male 
malaria-naïve donors from Barcelona in Spain. Ten milliliters of 
heparinized venous blood were collected from volunteers.
ethical approval
Written informed consent was obtained from all study partici-
pants. This study was approved by the Medical Research Advisory 
Committee in PNG (MRAC 08.02) and by the Hospital Clinic of 
Barcelona Ethics Review Committee (Comitè Ètic d’Investigació 
Clínica), Spain.
isolation of Plasma and PBMc
Plasma was separated from the cellular fraction of blood within 
4 h of collection by centrifugation at 600 g for 10 min at room 
temperature, aliquoted and stored at −80°C. Blood cells were fur-
ther fractioned in a density gradient medium (Histopaque-1077, 
Sigma-Aldrich) to obtain PBMCs that were frozen in fetal calf 
serum and 10% dimethyl sulfoxide and stored in liquid nitrogen 
until analysis. PNG samples were shipped to and analyzed at the 
Barcelona Institute for Global Health (Spain).
serological classification of intensity of 
Malaria exposure
We had previously examined malaria antibody responses in 
293 pregnant women from PNG (18). A Luminex microsphere 
technology-based assay measured IgG responses to Plasmodium 
falciparum (Pf) apical membrane antigen 1 (AMA1), merozoite 
surface protein 1 (MSP-119), and region II of the 175 kDa erythro-
cyte binding protein (EBA175); as well as Plasmodium vivax (Pv) 
merozoite surface protein 1 (MSP-119) and Duffy binding protein, 
all expressed in Escherichia coli. Antibody levels were expressed 
as median fluorescence intensity (MFI). For an in-depth B cell 
analysis, we selected a subset of individuals with diverse antibody 
TaBle 1 | Characteristics of study participants by malaria exposure category.
non-exposed (n = 9) low-exposed (n = 26) high-exposed (n = 29)
Agea 45 (31–53) 23.5 (19–36) 25 (17–38)
Body mass index – 23.6 (12.6–29.9) 23.15 (18.6–31.6)
Gestational age (weeks) NA 24 (18–29) 24 (15–31)
Number of pregnanciesa NA 2 (1–4) 1 (1–7)
Proportion with spontaneous abortion NA 3.85 3.45
Proportion with moderate anemia (<11 mg/dL) – 88.46 82.76
Proportion with severe anemia (<7 mg/dL) 0 3.85 6.9
Proportion with previous malariab 0 23.08 13.79
Proportion with fever in the last 24 hb 0 7.69 3.45
Proportion with ITN useb NA 42.86 57.14
aData are medians (ranges) and were self-reported.
bSelf-reported.
ITN, insecticide-treated bed net.
-, data not available
NA, not applicable.
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profiles. We classified malaria exposure as high or low according 
to the magnitude and breadth of antibody levels. We used serol-
ogy as an indirect measure of both recent and past cumulative 
exposure to Plasmodium to build a classifier for exposure levels. 
It is well established in malaria that with cumulative exposure 
there is an increase in the breadth of response to Pf and Pv anti-
body levels (35–40). For magnitude, IgG responses were divided 
in tertiles and ranked from 1 (low) to 3 (high) for each of the five 
antigens. For breadth, combined responses ranking from 5 to 9 
were classified as low exposure, and those ranking from 10 to 15 
as high exposure (Figure S1 in Supplementary Material). We then 
randomly selected 55 among the 293 malaria-exposed women; 
29 were highly exposed and 26 had low exposure.
Phenotyping and gating strategy
Peripheral blood mononuclear cells were thawed, and their 
viability measured on a Guava® Cytometer using Guava ViaCount 
Reagent (Millipore, Madrid, Spain). All samples had viabilities 
>60% and were used for the assays. All antibodies and reagents 
were purchased from BD Biosciences (Madrid, Spain), unless 
otherwise indicated. For compensation controls, BD Comp Beads 
were used. Cells and beads were acquired on a BD LSR II Fortessa 
cytometer.
One million PBMCs per sample were used for B cell staining. 
Cell suspensions were stained with LIVE/DEAD® Fixable Aqua 
Dead Cell Stain Kit (Invitrogen, Madrid, Spain), washed and 
blocked with PBS-BSA 0.05%. After washing, cells were stained 
in four multiparametric panels having a core panel with the 
following antibodies: anti-CD3 Horizon v500 (clone UCHT1), 
anti-CD14 Horizon v500 (clone M5e2), anti-CD16 Horizon 
v500 (clone 3G8), anti-CD19 PE/CF594 (clone HIB19), anti-IgD 
allophycocyanin/H7 (clone IA6-2), anti-CD27 allophycocyanin 
(clone M-T271), anti-surface IgD-APC/H7 (clone IA6-2), anti-
CD21 FITC (Beckman Coulter, clone BL13), anti-CD38 PerCP 
(clone HIT2), and anti-CD10 BV421 (BioLegend, clone HI10a). 
The additional sets of antibodies added to the core panel were 
as follows: (1) anti-surface IgM PE (clone G20-127), anti-sIgG 
PE/Cy7 (clone G18-145), rat anti-mouse b220 Alexa Fluor 700 
(clone RA3-6B2), and anti-PD1 BV605 (clone EH12.2H7); 
(2) anti-CD150 PE (clone A12), anti-CD95 PE/Cy7 (clone 
DX2), anti-CD40 Alexa Fluor 700 (clone 5C3), and anti-TACI 
BV605 (BioLegend, clone 1A1); (3) anti-CCR3 PE (clone 5E8), 
anti-CD71 PE/Cy7 (eBioscience, clone OKT9), anti-CXCR3 
Alexa Fluor 700 (clone 1C6), and anti-CD62L BV6054 (clone 
DREG-56); and (4) anti-CD80 Alexa Fluor 700 (clone L307.4) 
and anti-CD86 PE/Cy7 (clone 2331).
Fluorescence-minus-one controls were used for gating of 
positive events (Figure S2 in Supplementary Material). Samples 
were stained containing all the antibodies of the panel except 
one marker. These samples were used to determine the negative 
population for each staining experiment. Figure 1 shows the gat-
ing strategy used for this study. Lymphocytes were gated using 
a time event gate, excluding duplets. Live B cells were displayed 
according to CD19+ expression and a dump channel containing 
a viability marker, CD3, CD14, and CD16. Mature viable B cells 
(VBC) were gated through a Boolean gate containing live B cells, 
CD19+, and not CD10+ cells. Immature B cells contained CD19+, 
CD10+, and not CD38++. VBC were further divided into switched 
(IgD−) or unswitched (IgD+) populations, and plasmablast and 
germinal center cells (PCGC) (IgD−CD38++) (Figure 1). Switched 
and unswitched populations were displayed according to their 
expression of CD21 and CD27, and MBC classified as active 
(CD21−) and resting (CD21+). Unswitched (IgD+) population 
was divided as naïve B cells, MZ-like MBC and active naïve. The 
switched (IgD−) population was classified as active classical MBC 
(acMBC), resting classical MBC (rcMBC), active atypical MBC 
(aaMBC), and resting atypical MBC (raMBC) (Figure 1). Every 
B cell subset was expressed as percentage of total VBC. Shifts in 
one B cell subset were accompanied by shifts in one or more other 
B cells subsets. Gating strategy and data analysis was performed 
on FlowJo software version 9.2 (Tree Star).
statistical analysis
Percentage cell population and frequency of marker expression 
were compared between three malaria exposure groups, non-
exposed, low- and high-exposed individuals, using Kruskal–
Wallis test plus Dunn’s pairwise post hoc test. Differences between 
exposed and non-exposed individuals were assessed with the 
Wilcoxon signed-rank test and adjusted for multiple comparison 
by the Benjamini and Hochberg method (41). To compare aMBC 
FigUre 1 | Gating strategy. Cell acquisition was performed on a BD LSR II Fortessa cytometer and data analyzed on Flow Jo (Tree Star). B cell classification was 
performed based on Boolean gates. Excluded population (CD3+CD14+CD16+ and viability marker); viable B cells (VBC) (CD19+ AND NOT Excluded); immature 
B cells (VBC AND CD10+); plasmablasts and germinal center cells (VBC AND NOT Immature AND IgD− AND CD38high); switched (VBC AND NOT Immature AND 
NOT CD38high AND IgD−); AC indicates active classical memory B cells (MBCs) (Switched AND CD21−CD27+); RC, resting classical MBCs (Switched AND 
CD21+CD27+); AA, active atypical MBCs (Switched AND CD21−CD27−); RA, resting atypical MBCs (Switched AND CD21+CD27−); unswitched (VBC AND NOT 
Immature AND NOT CD38high AND IgD+); naïve (Unswitched AND CD21+CD27−); active naïve (Unswitched AND CD21−CD27−) and marginal zone (MZ)-like B cells 
(Unswitched AND CD21+CD27+ AND IgM+).
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and MZ-like B cell frequencies, and marker MFI against the rest 
of B cell subsets, we used the Friedman test, with Dunn’s post hoc 
test. Analyses and figures were performed using Stata (StataCorp, 
2014, Statistical Software, College Station, TX, USA: StataCorp 
LP) and GraphPad Prism (La Jolla, CA, USA).
resUlTs
Malaria exposure is associated with 
Differences in Frequencies of circulating 
B cell subpopulations
Baseline population characteristics are described in Table  1. 
B  cell subsets were characterized (Figure  1) and compared 
between exposed and non-exposed controls (Table  2), spe-
cifically 9 malaria non-exposed, 26 malaria low-exposed, and 
29 malaria high-exposed pregnant women. We analyzed the 






19+CD10−IgD+CD21+CD27−); active naïve (CD3−CD14−CD16
−CD19+CD10−IgD+CD21−CD27−); MZ-like B  cells (CD3−CD1
4−CD16−CD19+CD10−IgD+CD21+CD27+IgM+); and immature 
B  cells (CD3−CD14−CD16−CD19+CD10+). B  cell classification 
was performed based on previous phenotyping experiments (19, 
TaBle 2 | B cell subpopulation percentages calculated as proportion of total 
viable B cells in malaria non-exposed (n = 9) and malaria-exposed (n = 55) 
individuals and 95% confidence interval.
B cell subsets not exposed exposed p*
% 95% ci % 95% ci
Naïve 39.66 31.7–47.6 31.67 28.2–35.2 0.11
Active naïve 1.78 0.0–3.5 3.25 2.7–3.8 0.005
MZ-like B cells 12.05 6.6–17.5 2.76 2.3–3.3 <0.001
Plasmablast and 
germinal center
1.21 0.6–1.8 8.98 7.2–10.7 0.023
Immature 7.8 5.3–10.3 4.04 3.1–5.0 0.962
Active atypical MBCs 1.54 0.2–2.9 9.08 7–11.2 <0.001
Resting atypical MBCs 8.42 5.4–11.5 15.75 12.7–17.8 0.002
Active classical MBCs 1.48 0.9–2.1 2.8 2.3–3.3 0.041
Resting classical MBCs 20.27 16.5–24.1 17.72 15.6–19.8 0.21
*p-Values adjusted for multiple testing by Benjamini and Hochberg method.
MZ-like B cells, marginal zone-like B cells; MBC, memory B cell.
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42). The classification of plasmablast and GC (or GC-like) cells 
follows the Bm1–5 gating strategy using IgD and CD38 (42); it 
is worth noting that the PCGC subpopulation represents a small 
fraction of circulating B cells, and that some pre-GC and recent 
GC B cells may be caught in the peripheral blood. Eight individu-
als had a Pf infection, measured by PCR, three individuals in the 
high-exposure and five individuals in the low-exposure groups. 
We found no significant differences in B cell subset frequencies 
and proportions of marker expression in infected versus non-
infected individuals, as shown before for aMBC or MZ-like 
B cells in this cohort (18) and as reported by others (3, 43) (Table 
S1 in Supplementary Material). Thus, individuals with infection 
were included in the overall analysis. As previously shown in 
the literature, frequencies of peripheral blood aaMBC, raMBC, 
acMBC, and PCGC were increased in exposed individuals 
(Table 2). We also confirmed the strong decline in the propor-
tion of circulating MZ-like B cells with malaria exposure. Overall, 
we did not find statistically significant differences in the B cell 
subset proportions between high- and low-exposed individuals. 
However, for aaMBC, raMBCs, and acMBC, the differences were 
greater when non-exposed were compared to individuals with 
high exposure than to those with low exposure (Figure 2). Based 
on these results, we focused our study on switched (atypical and 
classical) MBC and MZ-like B cells.
Malaria exposure alters atypical and 
classical MBc Phenotypes
We compared frequencies of B  cell subsets expressing mark-
ers of activation and co-stimulation (IgG, IgM, b220, CD40, 
CD150, CD80, and CD86), inhibition (PD1, CD95, and TACI) 
and migration (CD62L, CXCR3, CCR3, and CD71) between 
malaria-exposed and non-exposed individuals (Table  3; Table 
S2 in Supplementary Material) and between different categories 
of exposure and non-exposed (Figure  3). Non-statistically 
significant differences were detected between low-exposed and 
high-exposed pregnant women in IgG+ aaMBC or IgG+ acMBC 
frequencies, but IgG+ raMBC and IgG+ rcMBC expression was 
increased in highly exposed individuals (Figure 3A). IgM+ aaMBC 
and IgM+ raMBCs were not affected by exposure. However, 
IgM-expressing acMBC and rcMBCs had a marked reduction in 
frequency with increased malaria exposure (Figure 3B), as seen 
in previous studies on HIV-infected individuals (2).
PD1, a marker of T  cell activation and exhaustion, plays 
important roles in negative regulation of T  cell responses and 
maintenance of peripheral tolerance in malaria infection (25). 
Frequencies of PD1+ aaMBCS were significantly increased 
in exposed individuals (Table  3; Figure S3 in Supplementary 
Material), with higher frequencies of PD1+ aaMBCS in low and 
high-exposed compared to non-exposed volunteers (Figure 4A). 
No differences in the expression of this marker were observed 
for the other switched B  cell subsets. Increased expression of 
Fas/CD95 by circulating B cells has been related to MBC acti-
vation (16), described in chronic antigen exposure (15, 16, 19) 
and associated with induction of apoptosis (12). Frequencies 
of CD95+-expressing aaMBCs, raMBCs, acMBCs, and rcMBCs 
were increased in exposed individuals compared to non-exposed 
(Table 3; Table S2 in Supplementary Material). However, no sta-
tistically significant differences were found between high and low 
malaria-exposed groups (Figure 4; Figure S3 in Supplementary 
Material).
B cell activation by a T-dependent signaling pathway involves 
the interaction with co-stimulatory molecules: CD28 on T cells, 
CD80 and CD86 on B  cells. CD80 also binds to PD1 ligand 
(PD1L) providing a negative signal for proliferation and IgG 
secretion of normal B  cells. In contrast, CD86 enhances B  cell 
activity (44). Interactions of PD1L with its two ligands, PD1 and 
CD80, on T cells play a key role in controlling T cell activation, 
proliferation, anergy and apoptosis (45).
Triggering of CD80 specifically inhibits B  cell proliferation, 
whereas CD86 enhances B  cell activity (53). Malaria-exposed 
women had increased frequencies of CD80+ active and raMBCs 
and CD86+ resting atypical and classical MBC compared to non-
exposed (Table 3; Table S2 in Supplementary Material).
CD40 signaling is required for GC formation but, paradoxically, 
strong CD40 signaling causes B cells to become GC-independent 
MBCs. It also provides short-term rescue signals to avoid CD95-
induced death by upregulating antiapoptotic proteins (32, 46). 
We observed higher frequencies of CD40+ aaMBCs and CD40+ 
acMBCs in malaria-exposed compared to non-exposed individu-
als, with a tendency of increased frequencies with higher exposure. 
No effect of malaria exposure was observed on CD40+ resting 
classical or atypical MBCs (Figure 4; Figure S4 in Supplementary 
Material).
Transferrin receptor (CD71) is a cell surface molecule that 
regulates uptake of iron-bound transferrin by receptor-mediated 
endocytosis, is expressed in dividing cells and is a marker of 
B  cell endocytosis (18, 47, 48–50). Highly exposed individuals 
had increased frequencies of CD71+ aaMBCs compared to non-
exposed individuals (Figure 4A), but no other association with 
malaria exposure was found for CD71 expression in the remain-
ing switched B cell subsets (Table S2 in Supplementary Material).
B  cells downregulate expression of b220 (a glycoform of 
CD45R) after or during migration from follicular mantle zones 
to GCs and prior to reentering circulation (51). We found no 
statistically significant differences in the frequency of b220+ cells 
TaBle 3 | Phenotypic marker frequencies in malaria-exposed and non-exposed individuals.
aaMBc, mean (95% ci) raMBc, mean (95% ci) MZ-like B cells, mean (95% ci)
not exposed exposed p* not exposed exposed p* not exposed exposed p*
IgG 42.08 (23.3–60.8) 57.6 (51.7–63.4) 0.164 25.26 (14.8–35.6) 47.8 (42.5–53) 0.015 1.69 (0.4–2.9) 4.09 (2.4–5.7) 0.224
IgM 19.92 (5.8–34) 22.3 (17.3–27.2) 0.744 36.38 (22–50.7) 24.7 (20–29.3) 0.113 NA NA NA
b220 34.08 (13.4–54.7) 14.93 (10.6–19.2) 0.149 23.54 (9.9–37.1) 16.07 (11.8–20.2) 0.373 8.49 (3.7–13.2) 14.49 (12.2–16.7) 0.7
PD1 5.64 (1.2–10) 19.74 (15.6–23.8) 0.027 0.49 (0.2–0.7) 1.69 (1–2.3) 0.155 1.07 (0.1–2.1) 4.27 (2.3–6.2) 0.052
CD40 49.98 (31.6–68.3) 71.63 (65.6–77.6) 0.065 90.01 (80–99.9) 95.39 (93.8–96.8) 0.373 82.63 (71.1–94.1) 88.7 (86.2– 91.3) 0.299
CD95 44.13 (25.5–62.7) 83.84 (80.7–86.9) 0.002 21.56 (7–36.1) 63.73 (58.3–69) 0.002 29.67 (8.3–51) 45.77 (38.5–53) 0.109
TACI 74.42 (64.1–84.6) 66.1 (59.6–72.5) 0.665 76.55 (63.6–89.4) 70.68 (64.7–76.5) 0.697 90.1 (79.5–99.6) 74.76 (69.1–80.3) 0.047
CD150 17.04 (6.2–27.8) 14.62 (11.1–18) 0.702 10.31 (−1.6 to 22.3) 13.47 (9.9–16.9) 0.163 22.46 (−2.4 to 47.3) 36.49 (28.5–44.4) 0.109
CCR3 18.98 (5.1–32.8) 17.17 (11.4–22.8) 0.695 12.34 (−10.7 to 35.4) 14.18 (7.2–21.1) 0.372 13.11 (−8.5 to 34.8) 14.24 (7.6–20.8) 0.837
CXCR3 1.23 (0–2.5) 2.95 (1.6–4.2) 0.162 2.8 (0.8–4.8) 4.42 (1.4–7.4) 0.88 1.99 (0.4–3.5) 4.27 (1.7–6.7) 0.403
CD71 27.75 (14.2–41.2) 47.48 (41.4–53.5) 0.056 22.96 (1.9–43.9) 35.01 (28.5–41.5) 0.127 10.79 (−6 to 27.6) 15.06 (9.6–20.5) 0.164
CD62L 14.87 (10.6–19.1) 15.43 (12.1–18.6) 0.62 23.16 (13.4–32.8) 31.65 (26.7–36.5) 0.332 29.8 (15.9–43.7) 31.87 (26.8–36.8) 0.855
CD80 3.91 (1.4–6.3) 9.29 (7–11.4) 0.043 4.81 (2.2–7.3) 10.19 (8.3–12) 0.027 1.35 (0.8–1.8) 2.85 (2.2–3.4) 0.128
CD86 32.67 (18–47.3) 35.5 (30.8–40.1) 0.822 7.24 (−0.7 to 15.2) 19.57 (15.1–23.9) 0.009 9.19 (0.1–18.2) 12.39 (8.4–16.2) 0.162
Percentages of B cell subsets expressing specific marker were calculated as proportions of total B cell subset.
*p-Values adjusted for multiple testing by Benjamini and Hochberg method, comparing malaria-exposed and non-exposed individuals.
NA, not applicable; MBC, memory B cell; MZ, marginal zone; aaMBC, active atypical MBC; raMBC, resting atypical MBC.
aaMBCs (CD19+CD10−IgD−CD21−CD27−), raMBCs (CD19+CD10−IgD−CD21+CD27−), and MZ-like B cells (CD19+CD10−IgD+CD21+CD27+IgM+).
FigUre 2 | Malaria exposure is associated with changes in the frequencies of different B cell subsets. Beeswarm plots show B cell subset frequencies in the 
groups categorized by malaria exposure. No exposure (Not exposed; n = 9), low exposure (Low; n = 26), and high exposure (High; n = 29). Lines and whiskers 
represent median and interquartile range, respectively. Differences were assessed with Kruskal–Wallis test plus Dunn’s post hoc test comparing each exposure 
category (*p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001).
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between exposed and non-exposed individuals for any of the 
B cell subsets (Table S2 in Supplementary Material; Table 3).
Malaria exposure is associated with 
Upregulation of inhibitory Markers on 
Peripheral MZ-like and active naïve B 
cells
To investigate changes that drive the intense depletion of circulat-
ing MZ-like B cells in individuals chronically exposed to malaria, 
we analyzed the surface expression of activation, inhibition, 
and migration markers on peripheral MZ-like B  cells across 
exposure categories. PD1+ MZ-like B cells were more frequent in 
individuals with the highest malaria exposure level compared to 
non-exposed (Figure 5A). We also found increased proportions 
of IgG+, CD95+, and b220+ MZ-like B cells with malaria expo-
sure, although differences did not reach statistical significance 
(Figure 5A). The trans-membrane activator calcium modulator 
and cyclophilin ligand interactor (TACI), a B cell activation fac-
tor (BAFF) receptor, promotes the differentiation of B cells into 
FigUre 3 | Malaria exposure and surface expression of IgG and IgM in switched memory B cells (MBCs). Beeswarm plots show (a) IgG and (B) IgM expression on 
MBCs subsets across exposure categories: Not exposed (n = 9), Low (n = 26), and High (n = 29) exposure. Active atypical MBCs (CD19+CD10−IgD−CD21−CD27−); 
resting atypical MBCs (CD19+CD10−IgD−CD21+CD27−); active classical MBCs (CD19+CD10−IgD−CD21−CD27+); and resting classical MBCs 
(CD19+CD10−IgD−CD21+CD27+). Lines and whiskers represent median and interquartile range, respectively. Differences were assessed with Kruskal–Wallis test plus 
Dunn’s post hoc test comparing each exposure category (*p < 0.05, **p < 0.01, ***p < 0.001).
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plasma cells (41, 42). We found decreased proportions of TACI+ 
MZ-like B cells in the highly exposed group compared to the non-
exposed one (Figure 5A). In summary, malaria exposure reduced 
circulating MZ-like B  cells, increased expression of b220 and 
proapoptotic markers PD1 and CD95, and decreased expression 
of the activation marker TACI. Finally, we also found increased 
frequencies of CD95 and PD1 expression on active naïve B cells 
(Figure 5B; Table S2 in Supplementary Material).
aaMBcs express More inhibitory Markers 
compared to Other B cell subsets in 
Malaria-exposed individuals
We described the phenotypic profile of atypical aMBC and 
other B  cell subsets in malaria-exposed women to assess the 
effect of chronic exposure. For this objective, we included only 
malaria-exposed individuals in the analysis. As expected, aaMBC 
and acMBCs had the highest frequencies of IgG+ cells within 
the switched compartment, and IgM was highly expressed in 
unswitched B cells subsets (Table 3; Table S2 in Supplementary 
Material). PD1 was expressed on aaMBCs more than in any 
other B cell subset, both expressed as percentage of positive cells 
and MFI values (Figure 6). Frequencies and levels of expression 
of CD95 were similar between aaMBCs, acMBCs, rcMBS, and 
PCGC subsets, and higher compared to the rest of the subsets 
(Table  3; Figure  6A). PCGC had the highest percentage of 
CD71+ cells, followed by the other switched MBC (Table S3 in 
Supplementary Material; Figure 6A), but the highest magnitude 
of CD71 expression was found on aaMBCs (Figure 6B). aaMBCs 
and raMBCs had the highest CD80 expression, whereas the 
unswitched, MZ-like, naïve, and active naïve B  cells had the 
lowest frequency (Table 3; Table S2 in Supplementary Material).
In addition, as recent studies on the origin of aaMBCs sug-
gested that aaMBCs and acMBCs may come from the same 
precursor (14, 57), we analyzed paired expression of our mark-
ers in aaMBC and acMBC to assess hypothetical differences in 
marker expression. We found that aaMBC had higher frequencies 
of PD1+, b220+, IgM+, and CD86+ cells and lower proportions of 
CD62L+cells than acMBC (Figure S5 in Supplementary Material).
Finally, we found that MZ-like B cells had increased expression 
of TACI. TACI is expressed mostly on MZ-like B cells, CD27+ 
MBCs, and plasma cells (31, 52). Here, TACI was mainly present 
on MZ-like B  cells and rcMBCs and raMBCs, all expressing 
CD21 (Table 3; Table S2 in Supplementary Material; Figure 7). 
In addition, MZ-like B cells had lower frequencies of b220+ cells 
than the rest of the unswitched B cell subsets (Figure 7).
DiscUssiOn
Our findings confirm that the circulating B cell compartment of 
pregnant women with frequent Plasmodium antigen exposure is 
dramatically altered, likely because of modifications in the fre-
quency and phenotype of different B cell subsets due to chronic 
immune activation. Malaria exposure is associated with an 
increase of aaMBC and a decrease of MZ-like B cell frequencies 
in peripheral blood, as reported in HIV (51, 58) and previous 
malaria (20, 26) studies.
Individuals highly exposed to malaria had more PD1+, CD95+, 
CD80+, CD71+, and CD40+ aaMBC than malaria non-exposed 
individuals. Within the malaria-exposed, expression (% and/or 
MFI) of PD1 and CD95 was highest in aaMBCs, consistent with 
the higher expression of PCPD1, the signaling regulator of PD1, 
shown in aaMBCs (28). Individuals chronically infected with 
FigUre 4 | Malaria exposure is associated with changes in atypical memory B cells (MBCs) phenotypes. Graphs show the frequencies of PD1, CD95, CD40, 
CD71, and b220-expressing (a) active atypical MBCs (aaMBCs, CD19+CD10−IgD−CD2−CD27−) and (B) resting atypical MBCs (rcMBCs, 
CD19+CD10−IgD−CD21+CD27−) among malaria exposure categories: Not exposed (n = 9), Low (n = 26), and High (n = 29) exposure. Beeswarm plots with lines 
representing median and interquartile range, respectively. Differences were assessed with Kruskal–Wallis test plus Dunn’s post hoc test comparing each exposure 
category (*p < 0.05, **p < 0.01, ***p < 0.001).
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FigUre 5 | Malaria exposure and upregulation in inhibitory markers on marginal zone (MZ)-like and active naïve B cells. (a) MZ-like B cells 
(CD10−IgD+CD21+CD27+IgM+) expressing IgG, TACI, b220, CD95, and PD1 and (B) active naïve B cell expressing CD95 and PD1 in Non- (n = 9), Low- (n = 26), 
and High-exposed (n = 29) individuals. Beeswarm plots with lines representing median and interquartile range, respectively. Differences were assessed with 
Kruskal–Wallis test plus Dunn’s post hoc test comparing each exposure category (*p < 0.05, **p < 0.01, ***p < 0.001).
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Pf, HIV, HBV, or HCV, have higher PD1 expression on T cells, 
a marker of both activation and immune suppression (2, 11, 25), 
and its blockade is also a target for immune therapies in HCV and 
melanomas (45, 59, 61, 63). To the best of our knowledge, this is 
the first time that increased PD1 expression has been described 
on B  cell subsets in the context of chronic malaria exposure. 
In addition, increased expression of Fas/CD95 by aaMBC-like 
phenotypes has previously been found in HIV infection (13), 
rheumatoid arthritis disease (15) and active systemic lupus 
erythematosus (16). Malaria-related increase in CD95 and PD1 
expression on aaMBCs could be responsible for their increased 
susceptibility to cell death (64). However, this seems unlikely, as 
aMBCs are found at high frequencies in malaria-exposed popula-
tions (3, 14, 21, 25, 60).
Increased CD40 expression associated to malaria exposure 
might favor aaMBC survival, as strong CD40L stimulus of GC 
cells has resulted in production of antiapoptotic proteins, provid-
ing survival signals rescuing the GC B cells from CD95-induced 
death (46). PD1 and CD95 expression in constantly activated 
B  cells may be involved in mechanisms of immune inhibition 
rather than apoptosis (54) helping to establish tolerance to 
chronic infection and in agreement with previously detected 
higher expression of B cell survival genes in aaMBCs (28).
We also observed that malaria-exposed individuals had higher 
frequencies of CD80+ raMBC and CD80+ aaMBC than the non-
exposed individuals but only raMBC had higher proportions of 
CD86+ cells in the exposed group. Triggering of CD80 inhibits 
proliferation by upregulating the expression of proapoptotic 
molecules and downregulating levels of antiapoptotic molecules, 
whereas CD86 boost B  cell activity; both markers have been 
involved in apoptosis via the CD95/CD95L pathway (37, 55, 62). 
CD80 might interact with PD1L in a reverse signaling pathway 
that promotes B cell anergy, as seen on T cells (56). The mecha-
nisms establishing the balance between immune inhibition and 
cell death are complex, but both mechanisms seem to play a role 
in tolerogenic responses to infection (54).
The proportion of IgG+ aaMBCs did not change with malaria 
exposure, whereas IgG+ raMBC and IgG+ rcMBC proportions 
FigUre 7 | Distribution of expression of TACI and b220 B cell subpopulations in malaria-exposed individuals. Frequencies (%) expressed median and interquartile 
range of TACI-expressing B cells and b220-expressing B cells. Differences were assessed with the Friedman test plus Dunn’s post hoc test, comparing marginal 
zone (MZ)-like B cells versus every other B cell subset (*p < 0.05, **p < 0.01, ***p < 0.001). MBC, memory B cell; aaMBC, active atypical MBC; raMBC, resting 
atypical MBC; acMBC, active classical MBC; rcMBC, resting classical MBC; PCGC, plasmablast and germinal center cells.
FigUre 6 | Expression of PD1, CD95, CD71, and CCR3 in B cell subpopulations in malaria-exposed individuals. (a) Frequencies (%) expressed median and 
interquartile range, respectively, and (B) magnitude of expression, each bar represents the SE about the mean. Differences were assessed with the Friedman test 
plus Dunn’s post hoc test, comparing active atypical memory B cells (aaMBCs) versus every other B cell subset (N = 55; *p < 0.05, **p < 0.01, ***p < 0.001). MBC, 
memory B cell; raMBC, resting atypical MBC; acMBC, active classical MBC; rcMBC, resting classical MBC; PCGC, plasmablast and germinal center cells.
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increased with exposure levels. Chronic antigen exposure can 
cause downregulation of IgG surface levels after B cell receptor 
internalization via endocytosis in favor of transition to secretory 
Ig in activated B cells (9). We analyzed the expression of CD71 
as a marker of B cell endocytosis (18) and observed that CD71+ 
aaMBCs were more frequent in exposed individuals, suggesting 
that aaMBCs recognize and internalize fewer antigens than other 
switched B cell subsets (18). The correlation between the number 
of cell surface CD71 molecules and the rate of cell proliferation 
is well known (47), as seen in numerous oncogenic cells (31, 39, 
47–50). The increased frequencies of aaMBCs expressing CD71 
in malaria-exposed pregnant women suggests that aaMBCs may 
proliferate at a higher rate in malaria-exposed individuals and 
is consistent with the overall higher frequencies of aaMBC in 
these individuals. Whether aaMBCs have increased capacity to 
proliferate or the higher CD71 expression on these cells need 
further studies.
Peripheral MZ-like B  cells have been associated with 
T-independent immune responses and can undergo SHM 
(30, 31, 52). We confirmed decrease in circulating MZ-like B cell 
frequency (18, 26) and have shown, for the first time, TACI+ 
MZ-like B  cell frequency reduction and higher CD95 expres-
sion with increasing malaria exposure. TACI deficiency impairs 
antibody responses to polysaccharide antigens, which may 
explain the increased vulnerability to infection with encapsulated 
organisms associated with malaria (29, 65). Also, the observed 
exposure-dependent reduced frequencies of TACI+ MZ-like 
B  cells may jeopardize the production of long-lived antibody 
secreting cells (ASCs) at the expense of short-lived ASCs, as seen 
in malaria-exposed populations (66, 67) and is consistent with 
hypogammaglobulinemia, associated with deficiencies in TACI 
gene expression seen in common variable immunodeficiency 
disease (65). Also, highly exposed individuals have an increased 
frequency of IgG+ MZ-like B cells, although the difference was 
not statistically significant. This finding suggests that once 
TACI is activated after TLR-4 stimulation, there might be rapid 
T-independent antibody responses from peripheral MZ-like 
B  cells that constitute an efficient first line of defense. Then, 
TACI-expressing peripheral MZ-like B  cells upregulate CD95 
and CD95L, and suppress inhibitors of CD95, which could result 
in apoptosis, preventing long-lasting activation (52). To the best 
of our knowledge, this is the first time that dual expression of 
CD95 and IgG on MZ-like B  cells has been described in indi-
viduals with chronic antigen exposure. Although we propose 
that activated peripheral MZ-like B  cells activate cell death 
(52), which explains part of the lower proportion of circulating 
MZ-like B cells in malaria exposed, we cannot rule out that part 
of this may be because active MZ-like B cells could be located in 
lymphoid organs (31). Also, non-antigen-specific cells, like active 
naïve B cells, have increased expression of CD95 and PD1 with 
malaria exposure, suggesting that chronic infections may alter the 
phenotype, but this finding requires future studies. We did not 
find differential expression of migration markers in B cell subsets 
associated to malaria exposure.
The study of the origin of atypical MBCs has been controver-
sial, a study in malaria-exposed children reported that aMBCs 
and cMBCs may share similar rates of SHM, suggesting a shared 
origin (14) whereas other study suggested a different origin (68). 
We found differences in the expression of PD1, b220, CD86, 
CD62L, IgM, and IgG between acMBC and aaMBCs and we can 
speculate that acMBCs upregulate PD1, b220, CD86, and IgM 
and downregulate CD27 and CD62L to become aaMBC. But 
it also seems likely that a fraction of aaMBCS expressing b220 
and/or IgM may have a GC-independent development pathway. 
This hypothesis would be consistent with recent observations 
where IgM+ aaMBC (IgD−CD21−CD27−) subsets appear to have 
two origins: a large fraction sharing mutation profiles similar to 
acMBCs (14), and a fraction with a clonal relationship similar to 
MZ-like B cells (34, 69). We propose that in a context of chronic 
malaria exposure, MZ-like B  cells undergo GC-independent 
affinity maturation, by first upregulating b220 expression and 
then downregulating IgD, CD21, and CD27 to generate early 
IgM short-lived MBC (32, 42). This hypothesis accounts, in 
part, for the lower frequency of MZ-like B cells observed with 
increasing exposure and explains the similar IgM expression on 
active and resting aMBC found in all exposure levels. Recently 
published work has shown that Pf-specific IgM+ MBCs have 
a precursor relationship with IgM+ ASC, highlighting the 
importance of IgM+ B  cells as effective responders to malaria 
rechallenge (33).
Our study had some limitations that may influence the results. 
We previously studied this cohort of pregnant women and found 
no differences in the proportion of aMBC and circulating MZ-like 
B  cells between pregnant and non-pregnant malaria-exposed 
women (18). But pregnancy itself and sex could have had an effect 
on the expression of some markers between malaria-exposed 
pregnant women from PNG and non-exposed controls from 
Spain. We were incapable of providing non-exposed controls 
from PNG, as all women were somehow exposed to Plasmodium 
parasites; therefore exposure to other chronic infections in 
women from the Madang area could also have an effect. However, 
HIV prevalence is very low in the area. We were unable to provide 
absolute B cell counts, and frequencies were based on the total 
peripheral B cell population. Also, we analyzed total B cells and 
not Plasmodium-specific B  cells, but recent work show good 
correlation with decreased AMA1-specific B  cell frequencies 
and total B cells per milliliter of blood (69). Finally, the relatively 
small samples size may have had limited power to detect statisti-
cally significant differences between the low- and high-exposure 
groups.
We propose that malaria-associated expansion of active and 
resting aMBCs with increased expression of inhibitory PD1, 
CD95, and co-stimulatory CD80 in malaria-exposed women, 
coupled with increased CD71 and CD40 expression on aaMBCs, 
suggests that these cells are maintained in an anergic state (inhibi-
tory profile) rather than going to apoptosis or cell death, helping 
to reduce the immune activation, and establishing a tolerogenic-
like profile, as described on T cells (56, 70, 71). The expression of 
these markers seems to play a key role in establishing immune-
homeostatic mechanisms that inhibit chronically activated 
B cells while simultaneously maintaining high B cell frequencies. 
This mechanism would keep the B cell activation threshold high 
enough to control infection but impaired enough to tolerate it 
and prevent systemic inflammation.
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Plasmodium exposure decreased the frequencies of TACI 
expression and upregulated the frequencies of CD95 on circulat-
ing MZ-like B cells. TACI decreased frequency may result in a 
lack of capacity to generate long-lived antigen-specific IgG+ B 
cells, suggesting that increasing exposure leads to higher fre-
quency of GC-independent MBC formation, favoring the rapid 
appearance of short-lived IgM+ ASC. The upregulation of CD95, 
the increased frequencies of IgG and b220 suggest that MZ-like 
B cells are being activated. This marks the importance of MZ-like 
B cells as targets for antimalarial therapies and vaccine develop-
ment. However, functional assays should be performed to try 
to shed light on the exact mechanisms and role of aaMBCs and 
MZ-like B cells on chronic infections.
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